NewAmsterdam Pharma (NAMS) Invested Capital (2021 - 2026)

NewAmsterdam Pharma has disclosed Invested Capital across 6 years of filings, most recently posting $715.5 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $715.5 million, down 10.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $715.5 million (down 10.67% YoY), and the FY2025 annual result was $740.7 million, down 6.83% from the prior year.
• Invested Capital came in at $715.5 million for Q1 2026 at NewAmsterdam Pharma, down from $740.7 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $800.9 million in Q1 2025 to a low of $8414.1 in Q2 2023.
• The 5-year median for Invested Capital is $471.6 million (2022), against an average of $529.1 million.
• Across the five-year window, Invested Capital slumped 39.6% in 2023 and jumped 4884356.84% in 2024, its largest moves.
• NewAmsterdam Pharma's Invested Capital stood at $498.3 million in 2022, then plunged by 39.6% to $301.0 million in 2023, then surged by 164.15% to $795.0 million in 2024, then retreated by 6.83% to $740.7 million in 2025, then decreased by 3.41% to $715.5 million in 2026.
• The last three Invested Capital figures came in at $715.5 million (Q1 2026), $740.7 million (Q4 2025), and $772.4 million (Q3 2025), per Business Quant data.